Patent ID: 9593167
Date: 2017-03-14
CPC Classifications: A61K,A61P,C07K,G01N

Claim:
1. A method of treating a cell proliferative disorder comprising administering to an individual an effective amount of a pharmaceutical composition, wherein the pharmaceutical composition comprises an immunoconjugate and a pharmaceutically acceptable carrier, wherein the immunoconjugate comprises a humanized monoclonal antibody that binds to STEAP-1 that is covalently attached to a cytotoxic agent, wherein the antibody comprises(a) a heavy chain variable domain comprising: (1) an HC-FR1 comprising the amino acid sequence of SEQ ID NO:25; (2) an HVR-H1 comprising the amino acid sequence of SEQ ID NO:14; (3) an HC-FR2 comprising the amino acid sequence of SEQ ID NO:22; (4) an HVR-H2 comprising the amino acid sequence of SEQ ID NO:15; (5) an HC-FR3 comprising the amino acid sequence of SEQ ID NO:138; (6) an HVR-H3 comprising the amino acid sequence of SEQ ID NO:16; and (7) an HC-FR4 comprising the amino acid sequence of SEQ ID NO:24; and (b) a light chain variable domain comprising: (1) a LC-FR1 comprising the amino acid sequence of SEQ ID NO:17; (2) an HVR-L1 comprising the amino acid sequence of SEQ ID NO:11; (3) a LC-FR2 comprising the amino acid sequence of SEQ ID NO:18; (4) an HVR-L2 comprising the amino acid sequence of SEQ ID NO:12; (5) a LC-FR3 comprising the amino acid sequence of SEQ ID NO:19; (6) an HVR-L3 comprising the amino acid sequence of SEQ ID NO:13; and (7) a LC-FR4 comprising the amino acid sequence of SEQ ID NO:20, wherein the immunoconjugate has the formula Ab-(L-D)p, wherein: (a) Ab is the antibody; (b) L is a linker; (c) D is a drug moiety; and (d) p ranges from about 1 to 20, and wherein the cell proliferative disorder comprises cells that express STEAP-1.